[1] OHE Y,OHASHI Y,KUBOTA,et al.Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel,cisplatin plus gemcitabine,and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:Four-Arm Cooperative Study in Japan[J].Ann Oncol,2007,18(2):317.
[2] SHOJI T,TAKATORI E,OMI H,et al.Phase Ⅱ clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer(Tohoku Gynecologic Cancer Unit 101 Group Study)[J].Int J Gynecol Cancer,2011,21(1):44.
[3] ZHOU CF,MA T,SU Y,et al.UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer[J].Anticancer Agents Med Chem,2013,13(2):235.
[4] XIE FW,PENG YH,WANG WW,et al.Influence of UGT1A1 gene methylation level in colorectal cancer cells on the sensitivity of the chemotherapy drug CPT-11[J].Biomed Pharmacother,2014,68(7):825.
[5] SCHULZ C,BOECK S,HEINEMANN V,et al.UGTlAl genotyping:a predictor of irinotecan-associated side effects and drug efficacy[J].Anticancer Drugs,2009,20(10):867.
[6] HIROSE K,KOZU C,YAMASHITA K,et al.Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene[J].Oncol Lett,2012,3(3):694.
[7] DESAI AA,INNOCENTI F,RATAIN MJ.Pharmacogenomics:road to anticancer therapeutics nirvana[J].Oncogene,2003,22(42):6621.
[8] PARK SR,KONG SY,RHEE J,et al.Phase Ⅱ study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer:clinical and pharmacogenetic results[J].Ann Oncol,2011,22(4):890.
[9] TAKANO M,KATO M,YOSHIKAWA T,et al.Clinical signifiance of UDPglucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers:a prospective multi-institutional study[J].Oncology,2009,76(5):315.
[10] MINAMI H,SAI K,SAEKI M,et al.Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese:roles of UGT1A1*6 and *28[J].Pharmacogenet Genomics,2007,17(7):497.
[11] ONOUE M,TERADA T,KOBAYASHI M,et al.UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients[J].Int J Clin Oncol,2009,14(2):136.
[12] LI M,WANG Z,GUO J,et al.Clinical signifiance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer[J].Onco Targets Ther,2014,7:1653.
[13] STEWART CF,PANETTA JC,O'SHAUGHNESSY MA,et al.UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics,but not severe toxicity in patients receiving low-dose Irinotecan[J].J Clin Oncol,2007,25(18):2594.
[14] HOSKINS JM,GOLDBERG RM,Qu P,et al.UGT1A1*28 genotype and irinotecan-induced neutropenia:dose matters[J].J Natl Cancer Inst,2007,99(17):1290.
[15] SUGIYAMA T,HIROSE T,KUSUMOTO S,et al.The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer[J].Oncol Res,2010,18(7):337.
[16] TZIOTOU M,KALOTYCHOU,NTOKOU A.Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity:low dose does not protect from toxicity[J].Ecancermedicalscience,2014,8:428.
[17] HU ZY,YU Q,PEI Q,et al.Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia:low doses also increase risk[J].Clin Cancer Res,2010,16(15):3832.
[18] SAI K,SAWADA J,MINAMI H.Irinotecan pharmacogenetics in Japanese cancer patients:roles of UGT1A1*6 and *28[J].Yakugaku Zasshi,2008,128(4):575.
[19] DI PAOLO A,BOCCI G,POLILLO M,et al.Pharmaeokinetie and pharmaeo-genetic predictive markers of irinoteean activity and toxicity[J].Curr Drug Metab,2011,12(10):932.
[20] MARQUES SC,IKEDIOBI ON.The clinical application of UGTlAl pharmaeogenetic testing:gene-environment interactions[J].Hum Genomics,2010,4(4):238.
[21] MCLEOD HL,SARGENT DJ,MARSH S,et al.Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer:results from North American Gastrointestinal Intergroup Trial N9741[J].J Clin Oncol,2010,28(20):3227.
[22] GLIMELIUS B,GARMO H,BERGLUND A,et al.Prediction of irinotecan and 5-florouracil toxicity and response in patients with advanced colorectal cancer[J].Pharmacogenomics J,2011,11(1):61.
[23] TAKAHARA N,NAKAI Y,ISAYAMA H,et al.Uridine diphosphate glucuronosyl transferase 1 family polypetide A1 gene(UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer[J].Cancer Chemother Pharmacol,2013,71(1):85.